Delving into the Latest Updates on Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Other Diseases

Respiratory Diseases

Stem cell therapy

Autologous CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Autologous CAR-T	1
Stem cell therapy	1

Top 5 Target	Count

TAG-72(Tumor-associated glycoprotein 72)	1

主要目的：评价不同剂量的SCM-181注射液静脉输注治疗特发性肺纤维化（IPF）患者的安全性和耐受性。次要目的：评价不同剂量的SCM-181注射液静脉输注治疗特发性肺纤维化（IPF）患者的初步有效性，为后续临床研究推荐合适的治疗剂量。探索性目的：探索SCM-181注射液静脉输注治疗特发性肺纤维化（IPF）患者的免疫相关指标。在多次给药剂量递增和扩展阶段将根据情况增加PK/同位素或其他探索性指标。

[Translation]

Primary objective: To evaluate the safety and tolerability of different doses of SCM-181 injection for intravenous infusion in the treatment of patients with idiopathic pulmonary fibrosis (IPF). Secondary objective: To evaluate the preliminary effectiveness of different doses of SCM-181 injection for intravenous infusion in the treatment of patients with idiopathic pulmonary fibrosis (IPF) and to recommend appropriate therapeutic doses for subsequent clinical studies. Exploratory objective: To explore the immune-related indicators of SCM-181 injection for intravenous infusion in the treatment of patients with idiopathic pulmonary fibrosis (IPF). PK/isotope or other exploratory indicators will be added as appropriate in the multiple dose escalation and expansion phases.

Start Date-

Sponsor / Collaborator

Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.

100 Clinical Results associated with Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.

Login to view more data

100 Deals associated with Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.

Login to view more data

100 Translational Medicine associated with Yunnan Shunxi Regenerative Medicine Engineering Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Phase 2

Login to view more data